February 2009- Volume 5, Issue 2

In this Issue

Informatics

FDA e-data review in next Phase Forward

FDA e-data review in next Phase Forward

FDA extends use of Phase Forward’s WebSDM software in submission and review of electronic CDISC format data

Image is everything

Image is everything

PerkinElmer and IDBS aim to ease high-content screening analysis burdens with Columbus-ActivityBase integration

The release of FireFly

The release of FireFly

Prosolio and Indigo BioSystems create data conversion software for mass spec users

Delving downstream

Delving downstream

Ariadne integrates Pathway Studio with Illumina’s GenomeStudio software

Automation & Instrumentation

‘Simple but elegant’ system

‘Simple but elegant’ system

UT Southwestern Medical Center to use WaferGen’s SmartChip system to identify gene expression biomarkers involved in wound healing

Test tube trials

Test tube trials

VistaGen, Capsant merge stem cells, cell culture and measurement tools for new screening platform

A sign of the times?

A sign of the times?

LabAutomation 2009 doesn’t skip a beat with strong year-opening event

BioTrove, Cisbio enter screening services distribution deal

BioTrove, Cisbio enter screening services distribution deal

Companies will combine Cisbio’s HTRF with BioTrove’s RapidFire mass spec platform

Culture for growth

Culture for growth

Hamilton, GCS collaboration yields high-density cell culture product

Genomics & Proteomics

Breathing new life into pipeline

Breathing new life into pipeline

Alnylam and Cubist enter into partnership to develop RNAi therapeutics for respiratory syncytial virus infection

They’re locked and loaded

They’re locked and loaded

RNA deal with Wyeth could mean as much as $847 million to Santaris even before royalties

Cardio candidates

Cardio candidates

Mutant gene puts South Asians at much higher risk of heart disease

NCI planning to look far and (genome) wide

NCI planning to look far and (genome) wide

Agency plans to award up to $96 million for multicenter genome-wide association studies

Running interferon

Running interferon

Bristol-Myers Squibb, ZymoGenetics PEG-Interferon lambda deal could be worth $1 billion

Research & Development

Town meets gown in J&J-Vandy deal

Town meets gown in J&J-Vandy deal

Janssen Pharmaceutica and Vanderbilt University forge industry-academia research partnership

Healing the wounded

Healing the wounded

OmegaGenesis, Mayo Clinic to develop nanomaterials for angiogenesis applications

Is nanotechnology safe?

Is nanotechnology safe?

U.S. lawmakers address need for more risk research, oversight

PPD acquires Merck’s 130,000 square-foot vaccine lab

PPD acquires Merck’s 130,000 square-foot vaccine lab

PPD Inc. recently entered a strategic collaboration with Merck & Co. Inc. whereby it acquired the latter’s vaccine testing lab in Wayne, Pa.

Roche lines up at Synta’s CRACM gate

Roche lines up at Synta’s CRACM gate

Billion-dollar alliance to produce oral agents for arthritis, inflammatory diseases

Pfizer buys Wyeth for $68B

Pfizer buys Wyeth for $68B

Will cut 800 R&D jobs as company seeks reinvention in face of patent expirations

Global News

Out-of-pocket expense

Out-of-pocket expense

Lilly pays $1.4 billion to end Zyprexa probe, with cash earmarked for settlement

Of (bio)similar interests

Of (bio)similar interests

Teva and Lonza seek to capture a large chunk of the emerging biosimilars market

Playing hard to get

Playing hard to get

EXACT Sciences rejects $41 million acquisition offer, and Sequenom refuses to give chase

Warding off MS

Warding off MS

Apitope and Merck Serono to advance MS vaccine

Out of failure, opportunity

Out of failure, opportunity

The Medicines Company acquires Targanta for $42M

Editor's Focus

Does anyone know what 2009 holds?

Does anyone know what 2009 holds?

Heading for LabAutomation 2009 in Palm Springs, I was sure I would get a pulse on what folks in the industry felt about the financial crisis. But if I went with plenty of questions, I probably came back with a whole bunch more.

Patent News

Bayer sues Abbott over Humira; Abbott thanks them with their own lawsuit

Bayer sues Abbott over Humira; Abbott thanks them with their own lawsuit

Last month, Abbott Laboratories was sued by Bayer AG’s HealthCare unit, alleging that Abbott's best-selling drug Humira infringes on a Bayer patent. In one new twist, Abbott has sued Bayer AG’s HealthCare unit, claiming the Bayer patent is invalid, not infringed or unenforceable.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022